Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IC41 therapeutic vaccine in chronic HCV
NCT00601770Phase 2Completed
- Sponsor
- Valneva
- Start
- Feb 2006
- Primary completion
- Jul 2008
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
A Phase 2 trial of IC41 in hepatitis C (HCV), sponsored by Valneva. Started Feb 2006; status: completed.
02
Drugs
IC41
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00601770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00601770.